Literature DB >> 11158741

Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality.

R D LeClaire1, S Bavari.   

Abstract

Bacterial superantigens (BSAgs) cause massive stimulation of the immune system and are associated with various pathologies and diseases. To address the role of antibodies in protection against BSAgs, we screened the sera of 29 human volunteers for antibodies to the SAgs staphylococcal enterotoxin A (SEA), SEB, SEC1, and toxic shock syndrome toxin 1 (TSST-1). Although all volunteers had detectable levels of antibodies against SEB and SEC1, many (9 out of 29 volunteers) lacked detectable antibody to SEA or had minimal titers. Antibody titers to TSST-1 were well below those to SEB and SEC1, and three volunteers lacked detectable antibody to this BSAg. In addition, pooled immunoglobulin preparations obtained from different companies had antibody titers against SEs and TSST-1. There was a good correlation between antibody titers and inhibition of superantigenic effects of these toxins. Transfer of SEB-specific antibodies, obtained from pooled sera, suppressed in vitro T-cell proliferation and totally protected mice against SEB. These data suggest that the inhibitory activity of human sera was specific to antibodies directed against the toxins. Thus, it may be possible to counteract with specific antibodies BSAg-associated pathologies caused by stimulation of the immune system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158741      PMCID: PMC90313          DOI: 10.1128/AAC.45.2.460-463.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  New uses for intravenous immune globulin.

Authors:  E R Stiehm
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

Review 2.  Superantigens: mechanism of T-cell stimulation and role in immune responses.

Authors:  A Herman; J W Kappler; P Marrack; A M Pullen
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

3.  Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment].

Authors:  S Takei; Y K Arora; S M Walker
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

Review 4.  Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

Authors:  U Andersson; L Björk; U Skansén-Saphir; J Andersson
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

Review 5.  Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy.

Authors:  Y Abe; A Horiuchi; M Miyake; S Kimura
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

6.  Divergence of human and nonhuman primate lymphocyte responses to bacterial superantigens.

Authors:  S Bavari; R E Hunt; R G Ulrich
Journal:  Clin Immunol Immunopathol       Date:  1995-09

7.  Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release.

Authors:  B G Stiles; S Bavari; T Krakauer; R G Ulrich
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

8.  Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay.

Authors:  G R Siber; J Leszcynski; V Pena-Cruz; C Ferren-Gardner; R Anderson; V G Hemming; E E Walsh; J Burns; K McIntosh; R Gonin
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

9.  Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion.

Authors:  A Achiron; R Margalit; R Hershkoviz; D Markovits; T Reshef; E Melamed; I R Cohen; O Lider
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

10.  In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins.

Authors:  M Toungouz; C H Denys; D De Groote; E Dupont
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

View more
  19 in total

1.  Structural basis of T-cell specificity and activation by the bacterial superantigen TSST-1.

Authors:  Beenu Moza; Ashok K Varma; Rebecca A Buonpane; Penny Zhu; Christine A Herfst; Melissa J Nicholson; Anne-Kathrin Wilbuer; Nilufer P Seth; Kai W Wucherpfennig; John K McCormick; David M Kranz; Eric J Sundberg
Journal:  EMBO J       Date:  2007-02-01       Impact factor: 11.598

2.  Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease.

Authors:  K Matsubara; T Fukaya; K Miwa; N Shibayama; H Nigami; H Harigaya; H Nozaki; T Hirata; K Baba; T Suzuki; A Ishiguro
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

3.  A novel loop domain in superantigens extends their T cell receptor recognition site.

Authors:  Sebastian Günther; Ashok K Varma; Beenu Moza; Katherine J Kasper; Aaron W Wyatt; Penny Zhu; A K M Nur-ur Rahman; Yili Li; Roy A Mariuzza; John K McCormick; Eric J Sundberg
Journal:  J Mol Biol       Date:  2007-05-18       Impact factor: 5.469

Review 4.  TCR recognition of peptide/MHC class II complexes and superantigens.

Authors:  Eric J Sundberg; Lu Deng; Roy A Mariuzza
Journal:  Semin Immunol       Date:  2007-06-07       Impact factor: 11.130

5.  Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock.

Authors:  Avanish K Varshney; Xiaobo Wang; Emily Cook; Kaushik Dutta; Matthew D Scharff; Michael J Goger; Bettina C Fries
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

6.  Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax.

Authors:  Wilbur H Chen; Marcela F Pasetti; Rajan P Adhikari; Holly Baughman; Robin Douglas; Jill El-Khorazaty; Nancy Greenberg; Frederick W Holtsberg; Grant C Liao; Mardi K Reymann; Xiaolin Wang; Kelly L Warfield; M Javad Aman
Journal:  Clin Vaccine Immunol       Date:  2016-12-05

7.  Bacterial Toxins-Staphylococcal Enterotoxin B.

Authors:  Bettina C Fries; Avanish K Varshney
Journal:  Microbiol Spectr       Date:  2013-12

8.  Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins.

Authors:  Kathryn L Jenko; Yanfeng Zhang; Yulia Kostenko; Yongfeng Fan; Consuelo Garcia-Rodriguez; Jianlong Lou; James D Marks; Susan M Varnum
Journal:  Analyst       Date:  2014-08-12       Impact factor: 4.616

9.  Induction of contact-dependent CD8(+) regulatory T cells through stimulation with staphylococcal and streptococcal superantigens.

Authors:  Amanda L Taylor; Elizabeth L A Cross; Martin J Llewelyn
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

10.  Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination.

Authors:  Ross D LeClaire; Robert E Hunt; Sina Bavari
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.